Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.
Positive results were announced from Novo Nordisk’s SUSTAIN 7 Phase III trial comparing once-weekly semaglutide against Lilly’s Trulicity for type 2 diabetes.
House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.
Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.
Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.
One year after emerging from stealth mode, immuno-oncology startup Arcus Biosciences struck an exclusive licensing deal with Shanghai, China-based Wuxi Biologics for its anti-PD-1 antibody GLS-010.
One day after committing to remain on the President’s Manufacturing Council, Johnson & Johnson Chief Executive Officer Alex Gorsky reversed course and resigned from the council, shortly before the council as a whole was disbanded by President Donald Trump.
Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).
The Trump administration will make cost-sharing payments to insurance companies under Obamacare for August 2017, a White House spokesman said, but the announcement did little to quell long-term concerns about the insurance market.
The FDA accepted for filing Seattle Genetics’ supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma.
Although the dust may have settled from a Canadian lawsuit Eli Lilly lost over patents for two of its drugs, Zyprexa and Strattera, questions remain over the manner in which the Indianapolis-based company fought in court.
Bristol-Myers Squibb released mixed top-line results from its Phase III CheckMate-214 clinical trial of Opdivo in combination with Yervoy for advanced or metastatic RCC.
W2O Sentient announced the appointment of respected industry leaders Dominic Viola as Managing Director, Client Services, and Michael Spitz as Practice Leader, Strategy.
Health insurance premiums for many customers on the Obamacare individual insurance markets would be 20 percent higher in 2018 if U.S. President Donald Trump follows through on a threat to stop billions of dollars of payments to health insurers, a nonpartisan congressional office said.
Many drugs granted accelerated approval and most high-risk medical devices approved by FDA lack clear evidence of safety and effectiveness, per JAMA reports.
Centene Corp., one of the largest players in the Obamacare individual insurance market, said it would offer Obamacare plans in Nevada in 2018.
Children who do not get enough sleep may be more likely to develop diabetes than kids who typically get enough shuteye, a UK study suggests.
South Carolina sued Purdue Pharma, accusing the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic.
Discovery Worldwide announced the appointment of Stephanie Franke as VP, Creative Director. Franke reports directly to TJ Cimfel, Group VP Creative Director.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.